Dihexa tends to interest adults focused on memory, cognitive performance, and healthy brain aging but because it's a potent research compound, whether it's appropriate for you is a careful clinical judgment, not a checklist
For research-peptide users, this is the single most important data drop since the original NEJM Phase 2 paper by Jastreboff and colleagues in 2023
Because the FDA removed semaglutide and tirzepatide from shortage in 2025, compounded versions now move through the personalization pathway, meaning a clinician documents a specific clinical reason, rather than mass copying of the brand drug
The opposing effects of GIP and GLP-1 on lipogenesis and lipolysis, respectively, help maintain adipocytes in young and healthy state, fostering higher levels of adiponectin a key adipokine known for its potential antidiabetic, anti-inflammatory, and antiatherogenic properties (185)